Elite in Myeloproliferative Neoplasms (MPN)

Dr. Olatoyosi M. Odenike

Hematology Oncology | Hematology | Oncology
The University Of Chicago
400 Skokie Blvd, Suite 300, 
Northbrook, IL 
Accepting New Patients
Offers Telehealth
Elite in Myeloproliferative Neoplasms (MPN)
The University Of Chicago
400 Skokie Blvd, Suite 300, 
Northbrook, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Olatoyosi Odenike is a Hematologist Oncology specialist and a Hematologist in Northbrook, Illinois. Dr. Odenike is rated as an Elite provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Myelofibrosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Odenike is currently accepting new patients.

Her clinical research consists of co-authoring 127 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 11 articles in the study of Myeloproliferative Neoplasms (MPN).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
The University Of Chicago Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

THE UNIVERSITY OF CHICAGO
400 Skokie Blvd, Suite 300, Northbrook, IL 60062
Other Locations
THE UNIVERSITY OF CHICAGO MEDICAL CENTER
5841 S Maryland Ave, Chicago, IL 60637

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
Phase 1 Study of Venetoclax in Combination With Decitabine 10-Day Regimen in Subjects With Acute Myeloid Leukemia
Phase 1 Study of Venetoclax in Combination With Decitabine 10-Day Regimen in Subjects With Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drugs: Decitabine, Venetoclax
Study Phase: Phase 1
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Phase II Study of Decitabine in Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2025
Intervention Type: Drug, Other
Study Drug: Decitabine
Study Phase: Phase 2
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
Enrollment Status: Completed
Publish Date: March 25, 2025
Intervention Type: Drug, Biological
Study Drugs: Entinostat, Pembrolizumab
Study Phase: Phase 1
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2024
Intervention Type: Drug
Study Drugs: CPI-0610 BET Small Molecule Inhibitor, Ruxolitinib
Study Phase: Phase 3
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

127 Total Publications

Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis.
Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis.
Journal: Blood cancer journal
Published: June 18, 2025
Similar Doctors
Brady L. Stein
Elite in Myeloproliferative Neoplasms (MPN)
Dr. Brady L. Stein
Hematology
Elite in Myeloproliferative Neoplasms (MPN)
Dr. Brady L. Stein
Hematology
233 E Superior St 1st Fl, Olson Pavilion, 
Chicago, IL 
 (19.6 miles away)
866-587-4322
Experience:
22+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brady Stein is a Hematologist in Chicago, Illinois. Dr. Stein has been practicing medicine for over 22 years and is rated as an Elite provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Polycythemia Vera, Myelofibrosis, Myeloproliferative Neoplasms (MPN), and Essential Thrombocythemia.

Distinguished in Myeloproliferative Neoplasms (MPN)
Dr. Regina M. Stein
Hematology | Oncology
Distinguished in Myeloproliferative Neoplasms (MPN)
Dr. Regina M. Stein
Hematology | Oncology
676 N St Clair St Ste 2140, Arkes Pavilion, 
Chicago, IL 
 (19.6 miles away)
866-587-4322
Experience:
24+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Regina Stein is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Stein has been practicing medicine for over 24 years and is rated as a Distinguished provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). Her top areas of expertise are Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Breast Cancer.

Distinguished in Myeloproliferative Neoplasms (MPN)
Dr. Jamile M. Shammo
Hematology | Oncology
Distinguished in Myeloproliferative Neoplasms (MPN)
Dr. Jamile M. Shammo
Hematology | Oncology
676 N St Clair St Ste 2140, Arkes Pavilion, 
Chicago, IL 
 (19.6 miles away)
866-587-4322
Experience:
40+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jamile Shammo is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Shammo has been practicing medicine for over 40 years and is rated as a Distinguished provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). Her top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome (MDS), Paroxysmal Cold Hemoglobinuria, Hemolysis, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Odenike's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 10 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile